Inicio>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Vebufloxacin (Flumenique)

Vebufloxacin (Flumenique)

Catalog No.GC33708

La vebufloxacina (Flumenique) (Flumenique; OPC7241; DM8966) muestra una potente actividad antibacteriana contra bacterias grampositivas y gramnegativas.

Products are for research use only. Not for human use. We do not sell to patients.

Vebufloxacin (Flumenique) Chemical Structure

Cas No.: 79644-90-9

Tamaño Precio Disponibilidad Cantidad
1mg
534,00 $
Disponible
5mg
1.057,00 $
Disponible
10mg
1.801,00 $
Disponible
20mg
3.171,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Vebufloxacin (Flumenique; OPC7241; DM8966) exhibits potent antibacterial activity against gram-positive and -negative bacteria.

A series of substituted 6,7-dihydro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acids is synthesized and tested for antibacterial activities. Among them, Vebufloxacin (OPC-7241) exhibits potent antibacterial activity against gram-positive and -negative bacteria, including Staphylococcus aureus and Pseudomonas aeruginosa, and OPC-7251 shows potent activity characteristically against Propionibacterium acnes[1].

[1]. Ishikawa H, et al. Studies on antibacterial agents. I. Synthesis of substituted 6,7-dihydro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acids. Chem Pharm Bull (Tokyo). 1989 Aug;37(8):2103-8.

Reseñas

Review for Vebufloxacin (Flumenique)

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Vebufloxacin (Flumenique)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.